Hytrin

(terazosin)

ApprovedSmall molecule

AAbbott

Hytrin is one of 141 small molecule programs targeting Urinary retention. It is currently in Approved.

Indications

Total Trials

Active Trials

140

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Urinary RetentionActive, not recruiting

Lower Urinary Tract SymptomActive, not recruiting

Stent Related SymptomsRecruiting

Alzheimer's DiseaseNot yet recruiting

AdultActive, not recruiting

Pilot StudyCompleted

Parkinson's DiseaseRecruiting

Motor FunctionNot yet recruiting

Urinary RetentionPreclinical

Active, not recruiting

Lower Urinary Tract SymptomPreclinical

Active, not recruiting

Stent Related SymptomsPhase 3

Recruiting

Alzheimer's DiseasePhase 2

Not yet recruiting

AdultPhase 1

Active, not recruiting

Pilot StudyPreclinical

Completed

Parkinson's DiseasePhase 3

Recruiting

Motor FunctionApproved

Not yet recruiting

Competition

Competitive Landscape

127 competitors in Adult

#DrugCompanyPhaseTrials

Hytrin

AAbbott

Approved

1 2

Tebrazid

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Phase 3

1 3

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 4

Mounjaro

Eli Lilly

Phase 2

1 5

Rifampicin

Boehringer Ingelheim

Phase 3

3 6

Myqorzo

CCytokinetics

Phase 3

1 7

Opzelura

DDizal Pharmaceuticals

Phase 2

1 8

Cabenuva

GSK

Phase 1

6 9

Skyclarys

Biogen

Phase 1

3 10

Sunlenca

Gilead

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Stent Related Symptoms

NCT06966804

Q3 2031

Phase 2Not yet recruiting

Parkinson's Disease

NCT07464028

Phase 3Recruiting

Parkinson's Disease

NCT07207057

Q3 2032

Phase 2Not yet recruiting

Alzheimer's Disease

NCT07796308

Clinical

Trials by Indication[1]

Parkinson's Disease4 trials

Terazosin Effect on Cardiac Changes in Early Parkinson's Disease

Active, not recruiting·—·Phase 2·NCT04386317·15 enrolled

A Pilot Study of Terazosin for Parkinson's Disease

Completed·JJordan Schultz·Phase 1/2·NCT03905811·13 enrolled

Terazosin And Metabolic Energetics in Parkinson's Disease

Not yet recruiting·NNandakumar Narayanan·Phase 2·NCT07464028·120 enrolled

Show 1 more trial

Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial

Recruiting·UUniversity College, London·Phase 3·NCT07207057·1,200 enrolled

Antidepressants1 trial

Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin

Completed·TThomas Jefferson University·Phase 4·NCT00449683·23 enrolled

Adult1 trial

Target Engagement of Terazosin in Healthy Adults

Active, not recruiting·UUniversity of Iowa·Phase 1·NCT04551040·18 enrolled

Urinary retention1 trial

Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up

Terminated·HHospital Authority, Hong Kong·N/A·NCT00563485·120 enrolled

Pilot Study1 trial

Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating

Completed·TThomas Jefferson University·N/A·NCT00237510·15 enrolled

6 more indications

Safety and Efficacy1 trial

Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting

Unknown status·—·Phase 2·NCT03195673·160 enrolled

Motor Function1 trial

Motor Function Efficacy of Pharmacological Treatments Targeting Energy Metabolism, in Parkinson's Patients

Not yet recruiting·II.R.C.C.S. Fondazione Santa Lucia·Phase 4·NCT05855577·50 enrolled

Vascular Function1 trial

Diesel Exhaust and Vascular Function

Unknown status·UUniversity of Washington·N/A·NCT01508637·24 enrolled

Lower Urinary Tract Symptom1 trial

Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension

Completed·—·N/A·NCT00693199·360 enrolled

Alzheimer's Disease1 trial

Terazosin And Metabolic Engagement in Alzheimer's Disease

Not yet recruiting·QQiang Zhang·Phase 2·NCT07796308·100 enrolled

Stent Related Symptoms1 trial

Efficacy of Alpha Blockers (Terazosin vs Tamsulosin) in Reducing Ureteral Stent Related Symptoms - An Open-label, Randomized Controlled Trial

Recruiting·PPenang Hospital, Malaysia·Phase 3·NCT06966804·150 enrolled

Regulatory

FDA Approval Timeline[4]

Aug 7, 1987

HYTRIN

NDA NDA019057

Dec 14, 1994

HYTRIN

NDA NDA020347

Jul 29, 2024

TEZRULY

NDA NDA218139

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for terazosin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — terazosin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for terazosin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA218139). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Hytrin. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Abbott company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AAbbott

Patent Landscape[5]

Patent Cliff

Feb 1, 2041

Earliest patent expiration — generic entry possible after this date

Patent #Expires

12427108Feb 1, 2041

11224572Feb 1, 2041

Hytrin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2031

Q3 2032

Trials by Indication[1]

Parkinson's Disease4 trials

Antidepressants1 trial

Adult1 trial

Urinary retention1 trial

Pilot Study1 trial

Safety and Efficacy1 trial

Motor Function1 trial

Vascular Function1 trial

Lower Urinary Tract Symptom1 trial

Alzheimer's Disease1 trial

Stent Related Symptoms1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News